Research programme: anti-RSV therapeutics - Medivir ABAlternative Names: Anti-RSV therapeutics research programme - Boehringer Ingelheim; MIV 323; RSV fusion protein inhibitor - Medivir AB
Latest Information Update: 22 Dec 2016
At a glance
- Originator Boehringer Ingelheim (Canada)
- Developer Medivir AB
- Class Small molecules
- Mechanism of Action DNA-directed RNA polymerase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections